PMID- 25299115
OWN - NLM
STAT- MEDLINE
DCOM- 20150625
LR  - 20141010
IS  - 1676-5680 (Electronic)
IS  - 1676-5680 (Linking)
VI  - 13
IP  - 3
DP  - 2014 Sep 29
TI  - Expression of ezrin and moesin related to invasion, metastasis and prognosis of 
      laryngeal squamous cell carcinoma.
PG  - 8002-13
LID - 10.4238/2014.September.29.13 [doi]
AB  - We examined the expression of ezrin and moesin in laryngeal squamous cell 
      carcinoma (LSCC) and their correlation with patient clinicopathological 
      characteristics and overall survival. Immunohistochemical staining and reverse 
      transcription-polymerase chain reaction (RT-PCR) for ezrin and moesin were 
      applied to 60 carcinoma tissues, adjacent normal tissues, and 33 metastatic lymph 
      nodes. Survival functions were estimated using the Kaplan-Meier method and 
      compared by the log-rank test. RT-PCR demonstrated that the intensity ratios of 
      ezrin and moesin to beta-actin were higher in LSCC than in adjacent normal mucous 
      membrane (P < 0.05). Furthermore, intensity ratios were higher in cervical 
      metastatic lymph nodes than in LSCC (P < 0.05). Immunohistochemical staining 
      showed that ezrin and moesin were well distributed in the cell membrane and 
      cytoplasm. Expression was significantly different between LSCC and adjacent 
      normal tissues (P < 0.05); moreover, expression in the cervical metastatic lymph 
      nodes was higher than in LSCC (P < 0.05). Expression of ezrin and moesin was 
      significantly related to clinical stage, T stage, and cervical lymph node 
      metastasis (P < 0.05), except that moesin showed no significant relationship with 
      clinical stage (P > 0.05). Patients with negative ezrin and moesin expression had 
      a significantly longer overall survival time compared to patients with moderate 
      and intense ezrin and moesin expression (P < 0.001, P < 0.05). Ezrin and moesin 
      expression is related to LSCC invasion and metastasis, and may be important 
      molecular markers for predicting prognosis and therapeutic targets in LSCC 
      patients.
FAU - Wang, X
AU  - Wang X
AD  - Department of Otorhinolaryngology & Head and Neck Surgery, Second Hospital 
      Affiliated to Harbin Medical University, Harbin, China.
FAU - Liu, M
AU  - Liu M
AD  - Department of Otorhinolaryngology & Head and Neck Surgery, Second Hospital 
      Affiliated to Harbin Medical University, Harbin, China.
FAU - Zhao, C Y
AU  - Zhao CY
AD  - Department of Otorhinolaryngology & Head and Neck Surgery, Second Hospital 
      Affiliated to Harbin Medical University, Harbin, China chunyuanzhao@yeah.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140929
PL  - Brazil
TA  - Genet Mol Res
JT  - Genetics and molecular research : GMR
JID - 101169387
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Microfilament Proteins)
RN  - 0 (ezrin)
RN  - 144131-77-1 (moesin)
SB  - IM
MH  - Carcinoma, Squamous Cell/metabolism/*pathology
MH  - Cytoskeletal Proteins/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/metabolism/*pathology
MH  - Male
MH  - Microfilament Proteins/genetics/*metabolism
MH  - Middle Aged
MH  - *Neoplasm Invasiveness
MH  - *Neoplasm Metastasis
MH  - Prognosis
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2014/10/10 06:00
MHDA- 2015/06/26 06:00
CRDT- 2014/10/10 06:00
PHST- 2014/10/10 06:00 [entrez]
PHST- 2014/10/10 06:00 [pubmed]
PHST- 2015/06/26 06:00 [medline]
AID - gmr3972 [pii]
AID - 10.4238/2014.September.29.13 [doi]
PST - epublish
SO  - Genet Mol Res. 2014 Sep 29;13(3):8002-13. doi: 10.4238/2014.September.29.13.